Solventum (NYSE:SOLV) Given Buy Rating at BTIG Research

Key Points

• BTIG Research reiterated its “Buy” rating on Solventum and set a $95 price target, implying 8.66% upside from the prior close.
• Analyst sentiment is broadly positive: eight analysts rate the stock a Buy, with a consensus rating of “Moderate Buy” and an average target price of $92.80.
• Solventum exceeded quarterly expectations, reporting $2.55 in EPS versus $1.91 expected and $2.21 billion in revenue, up 2.2% year over year.

Solventum (NYSE:SOLV - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at BTIG Research in a report released on Monday, Benzinga reports. They presently have a $95.00 price objective on the stock. BTIG Research's price objective points to a potential upside of 8.66% from the company's previous close.

Other equities research analysts also recently issued research reports about the company. UBS Group raised their target price on Solventum from $95.00 to $101.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Piper Sandler upped their price objective on Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Stifel Nicolaus raised their price objective on Solventum from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. KeyCorp boosted their target price on Solventum from $93.00 to $102.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Finally, Wedbush lifted their price target on shares of Solventum from $94.00 to $101.00 and gave the company an "outperform" rating in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $92.80.

Solventum Price Performance

Solventum stock opened at $87.43 on Monday. The firm has a market cap of $14.88 billion, a PE ratio of 10.69, a price-to-earnings-growth ratio of 1.36 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The stock's fifty day moving average price is $85.15 and its two-hundred day moving average price is $76.58. Solventum has a one year low of $62.38 and a one year high of $94.16.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion for the quarter, compared to analysts' expectations of $2.15 billion. During the same quarter last year, the business earned $1.69 earnings per share. Solventum's revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts expect that Solventum will post 7.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Solventum

A number of hedge funds and other institutional investors have recently made changes to their positions in SOLV. United Services Automobile Association bought a new stake in shares of Solventum in the 1st quarter valued at $239,000. Woodline Partners LP boosted its position in shares of Solventum by 40.7% during the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company's stock valued at $888,000 after purchasing an additional 3,377 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Solventum by 167.0% during the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company's stock valued at $1,268,000 after purchasing an additional 10,425 shares in the last quarter. First Trust Advisors LP grew its stake in Solventum by 5.8% during the second quarter. First Trust Advisors LP now owns 257,727 shares of the company's stock worth $19,546,000 after purchasing an additional 14,151 shares during the period. Finally, Marshall Wace LLP bought a new stake in Solventum in the second quarter worth approximately $766,000.

Solventum Company Profile

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.